Manuel M Montero-Odasso1, Yanina Sarquis-Adamson2, Mark Speechley3, Michael J Borrie4, Vladimir C Hachinski5, Jennie Wells4, Patricia M Riccio6, Marcelo Schapira7, Ervin Sejdic8, Richard M Camicioli9, Robert Bartha10, William E McIlroy11, Susan Muir-Hunter12. 1. Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, London, Ontario, Canada2Schulich School of Medicine, Division of Geriatric Medicine and Dentistry, Department of Medicine, University of Western Ontario, London, Ontario, Canada3Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada. 2. Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, London, Ontario, Canada. 3. Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, London, Ontario, Canada3Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada. 4. Schulich School of Medicine, Division of Geriatric Medicine and Dentistry, Department of Medicine, University of Western Ontario, London, Ontario, Canada. 5. Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada4Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada. 6. Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada. 7. Program of Geriatric Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 8. Department of Electrical and Computer Engineering, University of Pittsburgh, Pittsburgh, Pennsylvania. 9. Department of Medicine, Division of Neurology, University of Alberta, Edmonton, Alberta, Canada. 10. Robarts Research Institute and Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada. 11. Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada. 12. Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, London, Ontario, Canada10Faculty of Health Sciences, School of Kinesiology, University of Western Ontario, London, Ontario, Canada.
Abstract
Importance: Gait performance is affected by neurodegeneration in aging and has the potential to be used as a clinical marker for progression from mild cognitive impairment (MCI) to dementia. A dual-task gait test evaluating the cognitive-motor interface may predict dementia progression in older adults with MCI. Objective: To determine whether a dual-task gait test is associated with incident dementia in MCI. Design, Setting, and Participants: The Gait and Brain Study is an ongoing prospective cohort study of community-dwelling older adults that enrolled 112 older adults with MCI. Participants were followed up for 6 years, with biannual visits including neurologic, cognitive, and gait assessments. Data were collected from July 2007 to March 2016. Main Outcomes and Measures: Incident all-cause dementia was the main outcome measure, and single- and dual-task gait velocity and dual-task gait costs were the independent variables. A neuropsychological test battery was used to assess cognition. Gait velocity was recorded under single-task and 3 separate dual-task conditions using an electronic walkway. Dual-task gait cost was defined as the percentage change between single- and dual-task gait velocities: ([single-task gait velocity - dual-task gait velocity]/ single-task gait velocity) × 100. Cox proportional hazard models were used to estimate the association between risk of progression to dementia and the independent variables, adjusted for age, sex, education, comorbidities, and cognition. Results: Among 112 study participants with MCI, mean (SD) age was 76.6 (6.9) years, 55 were women (49.1%), and 27 progressed to dementia (24.1%), with an incidence rate of 121 per 1000 person-years. Slow single-task gait velocity (<0.8 m/second) was not associated with progression to dementia (hazard ratio [HR], 3.41; 95% CI, 0.99-11.71; P = .05)while high dual-task gait cost while counting backward (HR, 3.79; 95% CI, 1.57-9.15; P = .003) and naming animals (HR, 2.41; 95% CI, 1.04-5.59; P = .04) were associated with dementia progression (incidence rate, 155 per 1000 person-years). The models remained robust after adjusting by baseline cognition except for dual-task gait cost when dichotomized. Conclusions and Relevance: Dual-task gait is associated with progression to dementia in patients with MCI. Dual-task gait testing is easy to administer and may be used by clinicians to decide further biomarker testing, preventive strategies, and follow-up planning in patients with MCI. Trial Registration: clinicaltrials.gov: NCT03020381.
Importance: Gait performance is affected by neurodegeneration in aging and has the potential to be used as a clinical marker for progression from mild cognitive impairment (MCI) to dementia. A dual-task gait test evaluating the cognitive-motor interface may predict dementia progression in older adults with MCI. Objective: To determine whether a dual-task gait test is associated with incident dementia in MCI. Design, Setting, and Participants: The Gait and Brain Study is an ongoing prospective cohort study of community-dwelling older adults that enrolled 112 older adults with MCI. Participants were followed up for 6 years, with biannual visits including neurologic, cognitive, and gait assessments. Data were collected from July 2007 to March 2016. Main Outcomes and Measures: Incident all-cause dementia was the main outcome measure, and single- and dual-task gait velocity and dual-task gait costs were the independent variables. A neuropsychological test battery was used to assess cognition. Gait velocity was recorded under single-task and 3 separate dual-task conditions using an electronic walkway. Dual-task gait cost was defined as the percentage change between single- and dual-task gait velocities: ([single-task gait velocity - dual-task gait velocity]/ single-task gait velocity) × 100. Cox proportional hazard models were used to estimate the association between risk of progression to dementia and the independent variables, adjusted for age, sex, education, comorbidities, and cognition. Results: Among 112 study participants with MCI, mean (SD) age was 76.6 (6.9) years, 55 were women (49.1%), and 27 progressed to dementia (24.1%), with an incidence rate of 121 per 1000 person-years. Slow single-task gait velocity (<0.8 m/second) was not associated with progression to dementia (hazard ratio [HR], 3.41; 95% CI, 0.99-11.71; P = .05)while high dual-task gait cost while counting backward (HR, 3.79; 95% CI, 1.57-9.15; P = .003) and naming animals (HR, 2.41; 95% CI, 1.04-5.59; P = .04) were associated with dementia progression (incidence rate, 155 per 1000 person-years). The models remained robust after adjusting by baseline cognition except for dual-task gait cost when dichotomized. Conclusions and Relevance: Dual-task gait is associated with progression to dementia in patients with MCI. Dual-task gait testing is easy to administer and may be used by clinicians to decide further biomarker testing, preventive strategies, and follow-up planning in patients with MCI. Trial Registration: clinicaltrials.gov: NCT03020381.
Authors: Martin F Lafleur; Philip L Jackson; Francine Malouin; Carol L Richards; Alan C Evans; Julien Doyon Journal: Neuroimage Date: 2002-05 Impact factor: 6.556
Authors: Gunhild Waldemar; Kieu T T Phung; Alistair Burns; Jean Georges; Finn Ronholt Hansen; Steven Iliffe; Christine Marking; Marcel Olde Rikkert; Jacques Selmes; Gabriela Stoppe; Norman Sartorius Journal: Int J Geriatr Psychiatry Date: 2007-01 Impact factor: 3.485
Authors: Manuel M Montero-Odasso; Brittany Barnes; Mark Speechley; Susan W Muir Hunter; Timothy J Doherty; Gustavo Duque; Karen Gopaul; Luciano A Sposato; Alvaro Casas-Herrero; Michael J Borrie; Richard Camicioli; Jennie L Wells Journal: J Gerontol A Biol Sci Med Sci Date: 2016-03-16 Impact factor: 6.053
Authors: M Montero-Odasso; M Schapira; C Varela; C Pitteri; E R Soriano; R Kaplan; L A Camera; L M Mayorga Journal: J Nutr Health Aging Date: 2004 Impact factor: 4.075
Authors: Manuel Montero-Odasso; Marcelo Schapira; Gustavo Duque; Enrique R Soriano; Roberto Kaplan; Luis A Camera Journal: BMC Geriatr Date: 2005-12-01 Impact factor: 3.921
Authors: Manuel Montero-Odasso; Afua Oteng-Amoako; Mark Speechley; Karen Gopaul; Olivier Beauchet; Cedric Annweiler; Susan W Muir-Hunter Journal: J Gerontol A Biol Sci Med Sci Date: 2014-09-02 Impact factor: 6.053
Authors: Andrea L Rosso; Andrea L Metti; Kimberly Faulkner; Mark Redfern; Kristine Yaffe; Lenore Launer; C Elizabeth Shaaban; Neelesh K Nadkarni; Caterina Rosano Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472